Vyne Therapeutics Inc (VYNE) Stock Price, Quote & News

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 775 7936

Website: vynetherapeutics.com

Address:

685 Route 202/206 N, Suite 301, Bridgewater, United States

hiTHit Feb. 3 at 4:03 PM

$VYNE A thief broke into my house and stole everything except my Vyne stock. This idiot thief probably doesn't want to get rich.🤓

0 · Reply

Stock__Hunter Feb. 3 at 3:04 PM

$VYNE 👀

1 · Reply

OfficialStocktwitsUser Feb. 3 at 2:26 PM

$VYNE RSI: 62.22, MACD: 0.0166 Vol: 0.01, MA20: 0.57, MA50: 0.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

hiTHit Feb. 2 at 3:44 PM

$VYNE There are too many people in our elevator and it can't go up. Please, first remove 10,000 people from the elevator immediately. You're not doing any good here anyway.

2 · Reply

hiTHit Jan. 29 at 5:01 PM

$VYNE I informed the CEO that I would sell my gold and invest in shares. He said to me, “Don't bother buying shares. I'll transfer the entire company to you in exchange for your gold.”🤓

0 · Reply

Rulaxx1574 Jan. 28 at 9:56 PM

$VYNE garbage

0 · Reply

hiTHit Jan. 28 at 5:17 PM

$VYNE Today I'm not writing nonsense again. Today I'm not unhappy again. Today this place isn't deserted again. As you might have guessed, the price isn't 0.57 USD today either.

2 · Reply

hiTHit Jan. 27 at 5:05 PM

$VYNE I have as much money as my IQ. My IQ score result was 1. I have the highest IQ, first class. I think the price should be first USD right now.🤓

1 · Reply

hiTHit Jan. 26 at 3:44 PM

$VYNE I went on a safari in Africa with a CEO. After a while, a lion started chasing us. As I was trying to run away from the lion, the CEO said to me: "You idiot, you can't run faster than a lion." I told him: "I'm not trying to run faster than the lion, I'm just trying to run faster than you to survive."🤓

2 · Reply

Stock__Hunter Jan. 25 at 3:12 PM

$VYNE

1 · Reply

VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript

Dec 17, 2025, 8:00 AM EST - 6 weeks ago

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

Nov 6, 2025, 8:00 AM EST - 3 months ago

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

Aug 14, 2025, 8:00 AM EDT - 6 months ago

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

Jul 30, 2025, 8:00 AM EDT - 6 months ago

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Jul 2, 2025, 7:45 AM EDT - 7 months ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

May 8, 2025, 8:00 AM EDT - 9 months ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Apr 25, 2025, 11:55 AM EDT - 10 months ago

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Apr 25, 2025, 8:00 AM EDT - 10 months ago

VYNE Therapeutics Provides Update on VYN202 Program

Mar 20, 2025, 8:00 AM EDT - 11 months ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 6, 2025, 8:00 AM EST - 11 months ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Participate in March Investor Conferences

Feb 19, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Jan 6, 2025, 7:30 AM EST - 1 year ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Dec 23, 2024, 7:30 AM EST - 1 year ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Sep 12, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Aug 14, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 26, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 13, 2024, 9:02 AM EDT - 1 year ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

May 9, 2024, 8:00 AM EDT - 1 year ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 1, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Mar 19, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 29, 2024, 8:00 AM EST - 2 years ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 21, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 16, 2024, 6:50 AM EST - 2 years ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI IBIO

Jan 10, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 3, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Nov 16, 2023, 4:03 PM EST - 2 years ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:45 AM EST - 2 years ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 1, 2023, 4:15 PM EDT - 2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Oct 30, 2023, 7:20 AM EDT - 2 years ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:05 AM EDT - 2 years ago

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Sep 6, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 18, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Attend BIO International Convention

May 11, 2023, 4:01 PM EDT - 2 years ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Apr 19, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023, 7:45 AM EDT - 3 years ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 22, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 9, 2023, 4:01 PM EST - 3 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Feb 28, 2023, 4:00 PM EST - 3 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 22, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 15, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

hiTHit Feb. 3 at 4:03 PM

$VYNE A thief broke into my house and stole everything except my Vyne stock. This idiot thief probably doesn't want to get rich.🤓

0 · Reply

Stock__Hunter Feb. 3 at 3:04 PM

$VYNE 👀

1 · Reply

OfficialStocktwitsUser Feb. 3 at 2:26 PM

0 · Reply

hiTHit Feb. 2 at 3:44 PM

$VYNE There are too many people in our elevator and it can't go up. Please, first remove 10,000 people from the elevator immediately. You're not doing any good here anyway.

2 · Reply

hiTHit Jan. 29 at 5:01 PM

$VYNE I informed the CEO that I would sell my gold and invest in shares. He said to me, “Don't bother buying shares. I'll transfer the entire company to you in exchange for your gold.”🤓

0 · Reply

Rulaxx1574 Jan. 28 at 9:56 PM

$VYNE garbage

0 · Reply

hiTHit Jan. 28 at 5:17 PM

$VYNE Today I'm not writing nonsense again. Today I'm not unhappy again. Today this place isn't deserted again. As you might have guessed, the price isn't 0.57 USD today either.

2 · Reply

hiTHit Jan. 27 at 5:05 PM

$VYNE I have as much money as my IQ. My IQ score result was 1. I have the highest IQ, first class. I think the price should be first USD right now.🤓

1 · Reply

hiTHit Jan. 26 at 3:44 PM

2 · Reply

Stock__Hunter Jan. 25 at 3:12 PM

$VYNE

1 · Reply

peepthestamp Jan. 24 at 6:46 AM

$VYNE

0 · Reply

hiTHit Jan. 23 at 3:30 PM

$VYNE The CEO of a company, who is actually a physician specializing in internal medicine, recommended to his patient that they take 2 doses of RSS daily to aid in their recovery.🤓

1 · Reply

pennyman27 Jan. 22 at 6:31 PM

$VYNE any info on this one here? Waters are calm

1 · Reply

bcbholdem Jan. 21 at 8:58 PM

$VYNE DOGDOODOO

0 · Reply

Rulaxx1574 Jan. 21 at 6:07 PM

$VYNE loser CEO!!

1 · Reply

hiTHit Jan. 21 at 5:13 PM

$VYNE The CEO asked the shareholders: "If I increase the price to 10 USD, will you do it?" The shareholders said, "We'll do whatever you want, right away," without finding out what to do.🤓

1 · Reply

phaa Jan. 20 at 7:47 PM

$VYNE When is the next reverse split?

3 · Reply

hiTHit Jan. 20 at 3:38 PM

$VYNE I had four alcohol tests. But all four results were negative. I think the alcohol I was using was counterfeit, and this is an illegal situation.

2 · Reply

Berkshireannhathaway1 Jan. 14 at 10:10 PM

$VYNE pop

0 · Reply

Rulaxx1574 Jan. 14 at 9:04 PM

$VYNE where are all the phony pumpers now?

0 · Reply

Rulaxx1574 Jan. 14 at 4:55 AM

$VYNE a complete turd!

0 · Reply

hiTHit Jan. 12 at 3:35 PM

$VYNE The CEO addressed the shareholders today as follows: "I have terrible news for you." Shareholders asked, sweating: "What happened?" The CEO said: "Unfortunately, I will never be able to do an RSS for you again."🤓

3 · Reply

Market Cap	18.84M
Revenue (ttm)	500,000.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,966.00%
Debt to Equity Ratio	0.00

Volume	370,200
Avg Vol	6,341,776
Day's Range	N/A - N/A
Shares Out	33.29M
Stochastic %K	60%
Beta	1.95
Analysts	Sell
Price Target	$2.00